Background: Prostate cancer is the second most common reason of mortality due to cancer among men in Poland. The study aimed to determine the waiting time for diagnosis and treatment of prostate cancer. Methods: The study was carried out on patients treated for prostate cancer from May 2014 to February 2015 at five oncological centres in Poland. The median waiting time was measured from the time cancer was suspected to the histopathological diagnosis (SDI), from the cancer suspicion to the start of treatment (STI) and from the diagnosis to the start of treatment (DTI). Results: 123 males treated for prostate cancer were included for analysis. The median time for SDI, STI and DTI was 7.7, 18.7 and 8.7 weeks, respectively. Place of residence ...
Background Up to now, there have been very few studies concerning delay issues in the treatment of b...
Objectives: Understanding the drivers of delays from diagnosis to treatment can elucidate how to red...
BACKGROUND: Little is known about the healthcare process for patients with prostate cancer, mainly b...
Prostate cancer is one of the most common cancers in men. The incidence of prostate cancer increases...
Background: The five-year relative survival rate in Poland is approximately 10% lower compared with ...
Prostate cancer is one of the most common diagnosed cancers in men and the waiting time has become a...
BACKGROUND: Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, ther...
Introduction: Treatment delay is a major problem of contemporary oncology. Knowing the time interval...
Introduction. Relative 5-year cancer survival rates in Poland are around 10% lower than the average ...
Background: Wait times in cancer diagnosis and treatment may significantly affect a patient’s treatm...
Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certa...
Objective: To examine the relation between socio-demographic and clinical factors, and time from con...
PurposeWatchful waiting (WW) is one option for men with clinically localized prostate cancer. We exa...
Prostate cancer is one of the most common diagnosed cancer in men and the waiting time has become an...
Background. Wealthy countries have observed in recent decades a fast-growing number of prostate pati...
Background Up to now, there have been very few studies concerning delay issues in the treatment of b...
Objectives: Understanding the drivers of delays from diagnosis to treatment can elucidate how to red...
BACKGROUND: Little is known about the healthcare process for patients with prostate cancer, mainly b...
Prostate cancer is one of the most common cancers in men. The incidence of prostate cancer increases...
Background: The five-year relative survival rate in Poland is approximately 10% lower compared with ...
Prostate cancer is one of the most common diagnosed cancers in men and the waiting time has become a...
BACKGROUND: Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, ther...
Introduction: Treatment delay is a major problem of contemporary oncology. Knowing the time interval...
Introduction. Relative 5-year cancer survival rates in Poland are around 10% lower than the average ...
Background: Wait times in cancer diagnosis and treatment may significantly affect a patient’s treatm...
Prostate cancer (PCa) is the second most common neoplasm in male patients. To date, there's no certa...
Objective: To examine the relation between socio-demographic and clinical factors, and time from con...
PurposeWatchful waiting (WW) is one option for men with clinically localized prostate cancer. We exa...
Prostate cancer is one of the most common diagnosed cancer in men and the waiting time has become an...
Background. Wealthy countries have observed in recent decades a fast-growing number of prostate pati...
Background Up to now, there have been very few studies concerning delay issues in the treatment of b...
Objectives: Understanding the drivers of delays from diagnosis to treatment can elucidate how to red...
BACKGROUND: Little is known about the healthcare process for patients with prostate cancer, mainly b...